ERS Genomics and IRBM sign CRISPR / Cas9 license agreement 20-May-2024 By Isabel Cameron CRISPR licensing company ERS Genomics and drug discovery firm IRBM have entered into a non-exclusive CRISPR/Cas9 license agreement.
Vertex and CRISPR Therapeutics advance towards EMA approval for exa-cel 26-Jan-2023 By Jane Byrne The European Medicines Agency (EMA) has validated the marketing authorization application of Vertex Pharmaceuticals and CRISPR Therapeutics for exa-cel.
DNA damage from CRISPR/Cas9 editing could lead to cancer, finds report 10-Aug-2018 By Maggie Lynch Gene editing with CRISPR/Cas9 can cause genetic damage to cells leading to possible cancer risks, the study reported.